TUMOUR INFLAMMATION-ASSOCIATED NEUROTOXICITY

This adverse event was reported 7 times

TUMOUR INFLAMMATION-ASSOCIATED NEUROTOXICITY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 LISOCABTAGENE MARALEUCEL 2 0.0023
1 AXICABTAGENE CILOLEUCEL 2 0.0002
2 BLINATUMOMAB 1 0.0001
3 IRINOTECAN HYDROCHLORIDE 1 0.0001
4 FLUDARABINE PHOSPHATE 2 0.0001
5 DURVALUMAB 1 0.0000
6 LEVETIRACETAM ORAL 2 0.0000
7 LEVETIRACETAM INJECTION 2 0.0000
8 CYTARABINE 1 0.0000
9 LEVETIRACETAM 2 0.0000
See all drugs enriched for association with TUMOUR INFLAMMATION-ASSOCIATED NEUROTOXICITY

TUMOUR INFLAMMATION-ASSOCIATED NEUROTOXICITY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD19-directed Chimeric Antigen Receptor [EPC] 2 0.0002
1 Programmed Death Ligand-1 Blocker [EPC] 1 0.0000
2 Alkylating Drug [EPC] 2 0.0000
3 Platinum-based Drug [EPC] 1 0.0000
4 Nucleoside Metabolic Inhibitor [EPC] 1 0.0000
5 Corticosteroid [EPC] 3 0.0000
6 Folate Analog Metabolic Inhibitor [EPC] 1 0.0000
See all drug classes enriched for association with TUMOUR INFLAMMATION-ASSOCIATED NEUROTOXICITY